Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $25.10	$48.67M	0.27	452,966 shs	N/A
GNFT GENFIT	$3.99 -2.9%	$3.88	$2.55 ▼ $6.42	$199.51M	1.14	3,908 shs	2,643 shs
IPHA Innate Pharma	$2.14 -2.1%	$1.94	$1.29 ▼ $3.51	$201.88M	0.22	13,103 shs	7,297 shs
OGI Organigram Global	$1.43 -8.3%	$1.43	$0.85 ▼ $2.08	$191.66M	1.45	913,543 shs	1.07 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLUE bluebird bio	0.00%	0.00%	0.00%	0.00%	-69.51%
GNFT GENFIT	0.00%	+6.40%	+3.77%	-4.77%	0.00%
IPHA Innate Pharma	0.00%	-2.06%	+18.28%	+0.95%	-2.51%
OGI Organigram Global	0.00%	-1.04%	-2.05%	+5.15%	-24.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLUE bluebird bio	1.9656 of 5 stars	3.1	0.0	1.1	1.7	1.3
GNFT GENFIT	2.1565 of 5 stars	3.5	3.0	3.3	0.0	0.0
IPHA Innate Pharma	2.2412 of 5 stars	3.7	2.0	2.4	1.7	0.0
OGI Organigram Global	1.0231 of 5 stars	0.0	2.0	1.6	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLUE bluebird bio	2.14	Hold	$25.75	418.11% Upside
GNFT GENFIT	3.00	Buy	$13.00	225.81% Upside
IPHA Innate Pharma	3.33	Buy	$11.00	415.22% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BLUE, OGI, IPHA, and GNFT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
GNFT GENFIT	$76.77M	2.60	$0.07 per share	57.04	$1.50 per share	2.66
IPHA Innate Pharma	$12.62M	15.59	N/A	N/A	$0.11 per share	19.41
OGI Organigram Global	$117.47M	1.63	N/A	N/A	$2.08 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	N/A
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.05	28.61	N/A	N/A	2.86%	-8.19%	-5.79%	N/A

Latest BLUE, OGI, IPHA, and GNFT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLUE bluebird bio	0.37	0.51	0.33
GNFT GENFIT	0.08	1.23	1.23
IPHA Innate Pharma	2.52	2.60	2.60
OGI Organigram Global	N/A	2.59	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLUE bluebird bio	87.43%
GNFT GENFIT	2.24%
IPHA Innate Pharma	0.16%
OGI Organigram Global	34.63%

Insider Ownership

Company	Insider Ownership
BLUE bluebird bio	1.40%
GNFT GENFIT	4.20%
IPHA Innate Pharma	31.89%
OGI Organigram Global	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
OGI Organigram Global	860	134.03 million	133.91 million	Optionable

BLUE, OGI, IPHA, and GNFT Headlines

Recent News About These Companies

Atb Cap Markets Issues Pessimistic Forecast for OGI Earnings

August 17 at 11:31 AM | marketbeat.com

OGI FY2025 EPS Forecast Reduced by Alliance Global Partners

August 17 at 10:02 AM | marketbeat.com

FY2028 Earnings Estimate for OGI Issued By Atb Cap Markets

August 17 at 3:19 AM | americanbankingnews.com

Organigram Global (NASDAQ:OGI) Cut to Sell at Wall Street Zen

August 17 at 2:15 AM | marketbeat.com

OGI FY2025 EPS Decreased by Alliance Global Partners

August 17 at 2:13 AM | americanbankingnews.com

Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

Organigram reports Q3 revenue $70.8M, consensus $68.04M

August 13, 2025 | msn.com

Organigram Posts Wider Loss, Eyes Profitability In Near Term

August 13, 2025 | benzinga.com

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

Organigram Reports Record Third Quarter Fiscal 2025 Results

August 13, 2025 | financialpost.comF

Organigram Global (OGI) Expected to Announce Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Organigram Global (OGI) to Release Quarterly Earnings on Wednesday

August 6, 2025 | marketbeat.com

Organigram Global (NASDAQ:OGI) Trading Up 3.8% - Should You Buy?

August 5, 2025 | marketbeat.com

Organigram Global Inc. (OGI) Expands Into U.S. THC Beverage Market Across 25 States

August 2, 2025 | msn.com

Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

August 1, 2025 | financialpost.comF

Organigram Global Inc. (OGI) Stock Price Today - WSJ

July 15, 2025 | wsj.com

Shareholders in Organigram Global (TSE:OGI) are in the red if they invested five years ago

July 9, 2025 | finance.yahoo.com

Organigram Expands U.S. Presence with Hemp-Derived THC Beverage Launch

July 8, 2025 | tipranks.com

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | financialpost.comF

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | businesswire.com

OGI Organigram Global Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BLUE, OGI, IPHA, and GNFT Company Descriptions

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

GENFIT NASDAQ:GNFT

$4.00 -0.11 (-2.77%)

As of 08/15/2025 03:51 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Innate Pharma NASDAQ:IPHA

$2.13 -0.05 (-2.06%)

As of 08/15/2025 03:55 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Organigram Global NASDAQ:OGI

$1.43 -0.13 (-8.33%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.03 (+1.75%)

As of 08/15/2025 07:19 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time